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Abstract
DNAmethyltransferases have been implicated in the regulation of virulence genes in a
number of pathogens. Relapsing fever Borrelia species harbor a conserved, putative DNA
methyltransferase gene on their chromosome, while no such ortholog can be found in the
annotated genome of the Lyme disease agent, Borrelia burgdorferi. In the relapsing fever
species Borrelia hermsii, the locus bh0463A encodes this putative DNA adenine methyl-
transferase (dam). To verify the function of the BH0463A protein product as a Dam, the
gene was cloned into a Dam-deficient strain of Escherichia coli. Restriction fragment analy-
sis subsequently demonstrated that complementation of this E. colimutant with bh0463A
restored adenine methylation, verifying bh0463A as a Dam. The requirement of bh0463A
for B. hermsii viability, infectivity, and persistence was then investigated by genetically dis-
rupting the gene. The dam-mutant was capable of infecting immunocompetent mice, and
the mean level of spirochetemia in immunocompetent mice was not significantly different
from wild type B. hermsii. Collectively, the data indicate that dam is dispensable for B. herm-
sii viability, infectivity, and persistence.
Introduction
Relapsing fever is an arthropod-borne disease caused by several species of spirochetal bacteria
in the genus Borrelia. While tick-borne relapsing fever is found in many endemic foci world-
wide, the burden of disease is most substantial in Africa where it ranks among the top ten
causes for hospitalization in Ethiopia, and among the top ten causes of mortality in children
under five in Tanzania [1, 2]. Several species of relapsing fever are found in North America and
cause sporadic illness, including the well-characterized species Borrelia hermsii [3]. The patho-
genesis of relapsing fever Borrelia spp. is distinct from that of the closely related agent of Lyme
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disease, Borrelia burgdorferi [4, 5]. Relapsing fever Borrelia spp. cause acute recurrent febrile
events that correspond to episodic high levels of bacteremia, whereas B. burgdorferi rapidly
migrate out of the bloodstream and into host tissues that results in various clinical syndromes
including arthritis, neuropathy, and carditis [6, 7]. B. burgdorferi and relapsing fever Borrelia
spp. share many orthologous genes and exhibit significant synteny on their chromosomes [8,
9]. Additionally, many genes are unique to either Lyme disease-type or relapsing fever-type
agents. The bh0463A gene of B. hermsii codes for a putative DNA adenine methyltransferase
(Dam), and is one example of a gene found only in relapsing fever-type spirochetes [9].
DNA methylation is a crucial component of cellular defense, protecting host cells from for-
eign invasion of DNA and restriction modification complexes. Methylation also serves a role in
the coordination and regulation of numerous cellular events, including the timing of DNA rep-
lication, partitioning of newly synthesized DNA, and DNA repair processes [10, 11]. In bacte-
ria, methylation of the N6 position of adenine is critical for epigenetic gene regulation. Dams
mediate the methylation of adenine in the 5’-GATC-3’ sequence shortly after DNA replication.
GATC sites on the newly synthesized strand are briefly unmethylated, allowing DNA-binding
proteins with affinity for the resultant hemi-methylated DNA to prevent further modification
at the GATC site [10]. Other DNA-binding proteins have an affinity for fully methylated
DNA, or for non-methylated DNA [11]. The differential DNA binding affinities of various pro-
teins results in transcriptional regulation of many genes. In multiple pathogens, epigenetic reg-
ulation by way of methylation is critical for colonization in various host microenvironments,
and for survival in the presence of the host’s immune response.
The role of Dam in virulence is increasingly being elucidated in other pathogens [10, 12]. In
Salmonella enterica, dam- strains have exhibited dysregulation of in vivo-expressed genes,
reduced ability to adhere to and invade intestinal epithelium, reduced secretion of effector pro-
teins via a type III secretion system, and membrane instability [13–16]. As a result, Salmonella
enterica dam- are avirulent in vivo [14, 15]. Likewise, certain dam- strains ofHaemophilus influ-
enzae demonstrated a reduced ability to adhere to endothelial cells, a reduced capability for cel-
lular invasion, and defective intracellular replication [17]. In vivo attenuation was also
observed during murine infection with dam- strains of Yersinia pestis and Yersinia pseudotu-
berculosis [18, 19]. In cases where Dam is essential for viability, Dam over-producing (DamOP)
mutants have been generated to evaluate the effects of methylation on virulence. DamOP strains
of Vibrio cholerae, certain strains of Yersinia pseudotuberculosis, and Pasteurella multocida
have also demonstrated in vivo attenuation [20, 21].
A few decades ago, researchers noted the presence of an adenine-specific methylation sys-
tem in relapsing fever Borrelia spp., but not in most strains of B. burgdorferi, after digestion of
genomic DNA with adenine methylation-sensitive restriction enzymes [22, 23]. While a puta-
tive adenine-specific methyltransferase was annotated in the published B. hermsii chromo-
some, no studies have verified the function of this predicted gene. Moreover, a role for Dam in
the pathogenesis of Borrelia spp. has not been evaluated to date. The well-documented role for
Dam in the virulence of other pathogens, and the fact that Dam was identified in relapsing
fever Borrelia spp. but not in B. burgdorferi, led us to hypothesize that Dam is dispensable for
B. hermsii viability and has a role in spirochetal pathogenicity during mammalian infection. In
this report, the putative B. hermsii Dam locus (bh0463A) was cloned into a dam- Escherichia
coli strain. Digestion with methyl-group sensitive restriction enzymes verified the Dam func-
tion of bh0463A. A dam- mutant clone of B. hermsii was then successfully generated, demon-
strating that bh0463A is dispensable for B. hermsii viability. The dam- mutant clone was
capable of not only infecting immunodeficient mice, but could also successfully establish per-
sistent infection in immunocompetent mice.
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Materials and Methods
Ethics statement
The experimental procedures involving strains of inbred mice were carried out in accordance
with the American Association for Accreditation of Laboratory Animal Care (AAALAC) pro-
tocol and the institutional guidelines set by the Office of Campus Veterinarian at Washington
State University (Animal Welfare Assurance A3485-01 and USDA registration number 91-R-
002). Washington State University AAALAC and institutional guidelines are in compliance
with the U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals.
Inbred mice were maintained at Washington State University (Pullman, WA, USA) in an
AAALAC-accredited animal facility. The Washington State University Institutional Animal
Care and Use Committee reviewed and approved the animal protocols associated with the cur-
rent studies.
Mice were monitored every 24 hours by lab animal care technicians, as well as every 24
hours post infection when investigators were performing phlebotomy. Animal health was
assessed by observing the general appearance of mice as well as their activity prior, during, and
after handling. Mice that displayed reduced activity after moving the cage, reduced withdrawal
of the hindlimb during bleeding, or had a rough haircoat were considered clinically affected.
No animals became severely ill (critically depressed or moribund) or died before or during the
experimental endpoint. All animals were euthanized with carbon dioxide, followed by the sec-
ondary method of cervical dislocation.
Bacterial strain and culture conditions
The isolation and characterization of B. hermsii DAH has been described [24, 25], and was
acquired as a gift from George Chaconas, who obtained it from Tom Schwan. All wild type and
mutant clones of B. hermsii were cultivated at 35°C under 1.5% CO2 in modified Barbour-
Stoenner-Kelly medium (BSK-II) supplemented with 12% rabbit serum (Accurate Chemical
and Scientific Corp., Westbury, NY) [26]. Selection of transformants and growth of the
bh0463Amutant clone was achieved with the addition of gentamicin (40 μg/mL). For in vitro
growth assays, B. hermsii was grown to late log phase and subcultured in triplicate to a cell den-
sity of 5 X 105 spirochetes per mL. Spirochetes were enumerated at 24 hour-intervals and
expressed as mean densities with standard deviation. Cell densities and growth phase were
monitored by visualization under dark-field microscopy using a Petroff-Hausser counting
chamber.
Verification of DNA adenine methyltransferase function
The plasmid pAE35, and a control plasmid pAE30, were generated to test the Dam activity of
bh0463A following transformation into a commercially available dam-/dcm- Escherichia coli
strain (New England Biolabs, Ipswich, MA). To generate pAE30, the 135 bp Borrelia hermsii
DAH flgB promoter (flgBp) was amplified as previously reported [27] with primers P233 and
P255 that possessed NdeI and HindIII sites, respectively (Table 1). The amplification product
was then cloned upstream of an aphI gene conferring kanamycin resistance (kanR) on the
pBSV2 [28] shuttle vector using the same restriction enzymes (New England Biolabs, Ipswich,
MA). The resultant flgBp/kanR locus on pBSV2 was then amplified with P246 and P287, and
cloned into the commercially available pJet1.2/blunt vector (Thermo-Fisher Scientific, Wal-
tham, MA). The final control plasmid pAE30 was verified by DNA sequencing.
To generate the dam complementation plasmid, pAE35, the putative dam locus bh0463A
was amplified with P847 and P848 producing an 892 bp product. No native promoter or
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ribosomal binding site (RBS) could be identified in the immediate upstream region of
bh0463A. As such, P847 included a 5’ RBS and a KpnI restriction enzyme linker. The flgBp/
kanR amplicon was generated using P255 and P846, the latter possessing a KpnI site. Both PCR
products were cleaned using a PCR cleanup kit (Qiagen, Valencia, CA) and digested with KpnI
(New England Biolabs). Following ligation of the two amplicons, a single kanR-bh0463A con-
struct driven by the B. hermsii flgB promoter was ligated to pJet1.2/blunt in a separate reaction.
The final pAE35 construct was verified by DNA sequencing.
Both plasmids were transformed into a commercially available dam-/dcm- E. coli strain
(New England Biolabs). Following plasmid extraction (Mini Kit, Qiagen), 300 ng of either plas-
mid (pAE30 or pAE35) were digested with DpnI, MboI, or Sau3AI (New England Biolabs).
The resulting DNA fragments were resolved with electrophoresis on a 1.8% agarose gel.
Vector construction
The plasmid vector, pMTKO, was constructed for the stable integration of an aacC1 gene con-
ferring resistance to gentamicin (gentR) into the DNA adenine methyltransferase gene at chro-
mosomal locus bh0463A (GenBank Accession Number NC_010673.1). A 2,085 base pair PCR
amplicon of the bh0463A locus was produced with primers P426 and P427 (Table 1), and
cloned into the pJET1.2/blunt vector backbone (Thermo-Fisher Scientific) to generate the plas-
mid pJET1.2/MT. Inverse PCR of pJET1.2/MT was performed using P428 and P429, which
possess BamHI and NheI 5’ restriction sites, respectively. Amplification of the B. hermsii DAH
flgB promoter (flgBp) was performed as described above, and cloned upstream of gent on
pBSV2G [29]. The 695 base pair flgBp-gent construct was then amplified from pBSV2G using
P408 and P218, which was cloned into the inverse PCR amplicon at the BamHI and NheI
restriction sites. Sequencing to verify the appropriate insert was performed using the standard
pJET1.2/blunt primers. The final construct, pMTKO, was propagated in E. coli DH5α cells,
and purified using a plasmid midikit (Qiagen).
Table 1. Oligonucleotides used in this study.
Primer Sequence (5’ to 3’)a
P218 CATTTCCTAGCTAGCTTAGGTGGCGGTACTTGGGTC
P233 ATTCATATGAACACCCTCTATATCACAAATT
P246 GCTAGCGCTCTGCCAGTGTTACAACC
P255 GTTAAGCTTGTTAAAGAAAATTGAAATAAACTTG
P287 GACGCCGGCATTACGAATTCGAGCTCGGT
P308 TAGGCCGGCACTAGTGCAAGAGCTATAGCATTAAGAGAATGGCTAAAG
P309 TAGGCCGGCTCCCCAGTGCTTCTTTTCCTTCCAACATC
P408 CCGGGGATCCTCTAGAGTCG
P426 TAGGGCGCGCCGTGGTTCTACAGAACCAAAAGTAGCTGCT
P427 TAGCTCGAGGGTCTCTTTAGCAGTCTCTGCCC
P428 TAGGGATCCAAAGGAGTATTAAATCTCCCATCTC
P429 TAGGCTAGCTGGTAAATATAAAAAGATTAGTCTTTATGA
P780 CATGCGAGCCTTCTAAACTACTAAATTTAC
P825 GAAGCAGATGTTTATAAAGTCAATAACTTATATC
P846 TAGGGTACCTTAGAAAAACTCATCGAGCATC
P847 TAGGGTACCGAGGGAGGTTTCCAT ATGAGCGTTGCAATACG
P848 TAGGACGTCCATCTTTACGCCTATCCAC
a Restriction sites are underlined and shown in bold.
doi:10.1371/journal.pone.0155798.t001
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Transformation and mutant characterization
Preparation of electrocompetent B. hermsii DAH cells and transformation were carried out as
described previously for B. burgdorferi [30, 31]. After electroporation, cells were immediately
placed in 5 mL pre-warmed BSK-II supplemented with 12% rabbit serum, and incubated for
24 hours at 35°C with 1.5% CO2. Culture volume was then increased to 50 mL with fresh
medium and the transformant pool was allowed to expand in a polyclonal pool in BSK-II
medium under selection with gentamicin (40 μg/mL) until the cell density reached approxi-
mately 1x108 spirochetes per mL. Clonal populations were obtained via 10-fold serial dilution
until the cell density was approximately 1 spirochete per mL. Two hundred μL of the resulting
diluted sample was plated in each well of a 96-well plate. Plates were incubated as described
above. Wells containing potential transformant clones were identified by media color change.
Transformant clones were PCR screened for the presence of gentR, and PCR-positive clones
were inoculated into 100 mL of fresh BSK-II under gentamicin selection in preparation for
DNA extraction (Midi Kit, Qiagen). DNA from clones of BhΔdam were subjected to PCR
using P825 and P780 primers, producing a 2,641 base pair amplicon that spans both upstream
and downstream of the disrupted bh0463A locus. The resultant product was purified with a
PCR cleanup kit (Qiagen), and the insertion site was verified via sequencing. The absence of
Dam activity in the bh0463Amutant was verified by digesting 500 nanograms of genomic
DNA extracted from wild type and mutant B. hermsii with either DpnI, MboI, or Sau3AI.
Resultant fragments were resolved with electrophoresis on a 0.7% SeaKem LE Agarose gel
(Lonza, Basel, Switzerland).
Murine infection
Male, C.B-17/IcrHsd-Prkdcscid (SCID) or C57/BL6NHsd (B6) mice of 4–6 weeks of age were
purchased from Harlan (Indianapolis, IN). Both murine strains have been previously used for
infection experiments involving B. hermsii [32–34]. The animals were inoculated with a B.
hermsii clone via subcutaneous injection within the interscapular region at 1x106 total spiro-
chetes per mouse, except for the infectious dose experiments when each mouse was inoculated
with approximately 1x105, 1x104, 1x103, 1x102, or 10 spirochetes. B. hermsii clones were pas-
saged no more than two times in vitro from frozen glycerol stocks prior to murine inoculation,
and both the mutant and wild-type inocula were composed of clonal populations of serotype
VlpA7. In order to confirm infection, blood was drawn from a mouse via maxillary or saphe-
nous bleed each day over the course of 3 or 10 days. Blood (10 μl) was cultured in 1 ml of
BSK-II containing Borrelia antibiotic cocktail (0.02 mg ml-1 phosphomycin, 0.05 mg ml-1
rifampicin and 2.5 mg ml-1 amphotericin B). Blood cultures were incubated at 35°C under
1.5% CO2 for 3–4 weeks. The blood cultures were periodically examined via dark-field micros-
copy for the presence of Borrelia cells. A mouse whose blood sample(s) showed viable spiro-
chetes via blood culture was considered infected.
Verification of the stable disruption of dam and antigenic variation
The stable integration of gentR into bh0463A was verified by PCR amplification and restriction
enzyme digest of mutant spirochetes recovered from mice. One mL blood cultures from mice
at day 10 post inoculation were verified positive by microscopy, and DNA was extracted with
the Wizard Genomic DNA Kit (Promega, Madison, WI) using the manufacturer’s instructions
for Gram negative bacteria. Recovered genomic DNA was then subjected to restriction enzyme
digestion with DpnI and MboI, and resultant fragments were electrophoretically resolved on a
1.8% agarose gel.
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The same DNA extracted from day 10 post inoculation blood cultures was used as template
in a PCR reaction with primers P308 and P309 to amplify the variable major protein expression
site. The resultant amplicon was resolved on a 1% agarose gel, and DNA was extracted using
the QIAquick Gel Extraction Kit (Qiagen). Extracted DNA was sequenced; results were com-
pared with the infecting serotype and analyzed on BLAST (http://blast.ncbi.nlm.nih.gov) to
verify antigenic switching.
Quantification of spirochetemia
Quantitative PCR (qPCR) of B. hermsii from mouse blood was demonstrated in a previous
study to correlate with microscopic counting of spirochetes on a Petroff-Hausser counting
chamber [35]. The qPCR protocol described herein was adapted from [35] and [36]. Total
DNA was extracted from 40 μL of mouse blood on days 3, 7, and 10 post inoculation using the
QIAamp DNAMicro Kit (Qiagen) following the handbook protocol for small volumes of
blood. DNA was eluted in 20 μL of distilled water, followed by dilution 1:10 with water. Five μL
of the diluted samples, 10 μL of 2X SsoAdvanced Universal SYBR Green Supermix (Bio-Rad
Laboratories, Hercules, CA), and 0.4 μL each of primers P677 and P678 (5’-TAACACACCAG
CATCACTAGCT, 5’-CCTTCCTCTTGCTGTCCTATCT, respectively; concentration
18.75 μM) were added to the 20 μL qPCR reaction volume. The 177 base pair product of P677
and P678 originates in the B. hermsii DAH flaB gene. Cycling parameters were one cycle at 98°
for 2 minutes, followed by forty cycles at 98° for 5 seconds and 62° for 25 seconds. Reactions
were run on the CFX96 Touch Real-Time PCR System (Bio-Rad). A standard curve was gener-
ated using the flaB PCR amplicon cloned into the vector pCR4-TOPO (Invitrogen, Carlsbad,
CA), diluted from 106 to 10 copies per 5 μL. The mean copy number was obtained from tripli-
cate measurements of both standards and samples, and multiplied by a factor of 1000 to quan-
tify spirochetes per mL of blood. The multiplication factor was obtained because DNA in 5 μL
undiluted sample = DNA in 10 μL blood; 10 μL blood x 100 = spirochetes in 1 mL x 10 (sample
dilution factor) = 10 X 100 = 1000.
Statistical analysis
The SigmaPlot program (version 11, Systat Software, San Jose, CA) was used for all statistical
analyses, except for linear regression analysis of growth curves where Microsoft Excel (version
2013) was used. Student’s t-test was used to compare the slopes of the linear regression lines
(growth curves) and when comparing the means of two groups (qPCR data). Fisher’s Exact
Test was used in cases where data could be applied to contingency tables (murine infection
data). P-values of<0.05 were considered statistically significant.
Results
Verification that bh0463A encodes a putative DNA adenine
methyltransferase
The presence of a DNA adenine-specific methylation system in relapsing fever Borrelia spp.
was discovered several decades ago by digesting genomic DNA with adenine methylation-sen-
sitive restriction enzymes DpnI and MboI [22, 23]. A later publication by Lescot et al. identified
a putative adenine-specific methyltransferase in the chromosome of Borrelia duttonii and B.
recurrentis [9]. For the present study, a BLAST analysis of the putative B. duttonii adenine-spe-
cific methyltransferase (bdu_467; GenBank Accession Number NC_011229.1) identified a
highly similar gene annotated as a ‘DNAmethyltransferase’ in the chromosome of B. hermsii
at locus bh0463A (Accession Number NC_010673.1). The same BLAST analysis also identified
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highly similar genes in several other species of relapsing fever (B. turicatae, B. parkeri, B. coria-
ceae, B. hispanica, B.miyamotoi, B. crocidurae, and B. persica), indicating that the putative ade-
nine-specific methyltransferase is conserved among relapsing fever Borrelia species. Further
characterization of this locus on the Restriction Enzyme Database website (http://rebase.neb.
com, New England Biolabs) concurred with the BLAST analysis, and identified the predicted
recognition sequence of the putative methyltransferase as GATC.
To verify the function of bh0463A as a DNA adenine methyltransferase, the predicted dam
gene was PCR amplified and cloned downstream of a B. hermsii flgB promoter-driven kanamy-
cin resistance cassette (kanR) in a pJet plasmid. This construct, pAE35, was then transformed
into a dam- E. coli strain. Likewise, a similar plasmid possessing only kanR, pAE30, was trans-
formed as a control. Plasmid DNA extracted from the dam- E. coli transformed clones was sub-
jected to digestion with either DpnI, MboI, or Sau3AI; DpnI cuts GATC sites in which the
adenine residue is methylated, MboI cuts unmethylated GATC sites, and Sau3AI cleaves all
GATC sites regardless of adenine methylation, but will not cut when cytosine is methylated.
The results demonstrated that, unlike the control plasmid, expression of bh0463A in the dam-
E. coli cells produced a restriction fragment profile indicative of adenine methylation at GATC
sites (i.e. permissive digestion by DpnI and Sau3AI only; Fig 1). These results provide strong
evidence for the function of bh0463A as a DNA adenine methyltransferase. Hereafter, the
bh0463A locus will be referred to as dam.
Fig 1. Complementation of bh0463A in a dam- Escherichia coli strain results in adeninemethylation of
plasmid DNA.Control plasmid pAE30 (lanes 1, 3, 5, and 7) and a bh0463A complementation plasmid
(pAE35; lanes 2, 4, 6, and 8) were extracted from a dam- E. coli strain and subjected to digestion with DpnI
(lanes 3 and 4), MboI (lanes 5 and 6), or Sau3AI (lanes 7 and 8). DpnI, MboI, and Sau3A1 cut GATC
sequences that are adenine methylated, adenine non-methylated, or cytosine non-methylated, respectively.
Sizes of selected molecular weight standards (mws) of 100 bp DNA ladder (New England Biolabs) are shown
on the left in base pairs.
doi:10.1371/journal.pone.0155798.g001
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Generation and in vitro characterization of a dammutant of B. hermsii
In order to determine whether Dam is dispensable for viability in B. hermsii, a mutant clone
with a disrupted dam gene (BhΔdam) was generated. To achieve this, a plasmid (pMTKO) was
constructed that contained a B. hermsii flgB promoter-driven aacC1 gene conferring resistance
to gentamicin (gentR) inserted within a copy of bh0463A at nucleotide position 410 (Fig 2).
Electrocompetent B. hermsii cells were transformed with the pMTKO construct, and resultant
transformants were isolated under gentamicin selection and PCR screened for the presence of
gentR. Final verification of the mutant clone was achieved through PCR amplification and
sequencing of the gentR insertion site.
To verify the disruption of Dam function in BhΔdam, genomic DNA from both mutant and
wild type strains was subjected to restriction digest by DpnI, MboI, or Sau3AI as described
above. The results demonstrated that BhΔdam DNA was resistant to digestion with DpnI, an
enzyme requiring methylation of adenine residues for GATC cleavage, whereas wild type DNA
was highly fragmented following digestion with DpnI (Fig 3). Conversely, BhΔdam genomic
DNA is fragmented after digestion with MboI, which is blocked by adenine methylation, while
wild type DNA is resistant to digestion with this enzyme. DNA isolated from both wild type B.
hermsii and BhΔdam was equally susceptible to fragmentation by Sau3AI, indicating that the
absence of dam in B. hermsii does not affect cytosine methylation at GATC sites. Together, the
data indicate that adenine methylation is disrupted in BhΔdam, and provides further confirma-
tion that bh0463A codes for an adenine-specific DNA methyltransferase.
To determine whether the disruption of dam results in altered growth during in vitro culti-
vation, growth curves were generated for in vitro-grown BhΔdam and wild type B. hermsii (Fig
4). During the 72 hours of exponential phase growth (day 1–4 post inoculation), the BhΔdam
doubling time was 9.8 hours while the doubling time for wild type B. hermsii was 10.5 hours.
Linear regression analysis of the slopes during these three days revealed no significant differ-
ences between the growth of the mutant and wild type strains (p = 0.6). Maximum cell densities
of both clones occurred at 5 days post inoculation (wild type = mean 1.4 x 108, 95% confidence
interval = 8.8 x 107–1.9 x 108; BhΔdam = 1.4 x 108, 95% CI = 8.3 x 107–1.9 x 108) and were not
significantly different (p = 0.9). Comparison of overall in vitro growth patterns between
BhΔdam and the wild type control revealed minimal differences, demonstrating that the dis-
ruption of dam does not result in in vitro growth defects.
BhΔdam is capable of persistent infection in mice
Previous studies involving dammutants in other bacterial species have demonstrated a role for
Dam in virulence and pathogenesis [10, 12, 37]. Thus, the ability of the BhΔdammutant clone
Fig 2. Schematic of the DNA adeninemethyltransferase locus (bh0463A) in B. hermsiiwild type (WT) and BhΔdam. The locations of
primers used to generate pMTKO and verify BhΔdam are depicted as arrowheads (see Materials and Methods). nt, nucleotide; up, upstream
sequence; dn, downstream sequence.
doi:10.1371/journal.pone.0155798.g002
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Fig 3. Disruption of putativemethyltransferase bh0463A results in unmethylated genomic DNA. Lanes
1, 3, 5, and 7 contain wild type B. hermsii DNA; Lanes 2, 4, 6, and 8 contain DNA from BhΔdam. DNA is either
undigested (lanes 1 and 2), digested with DpnI (lanes 3 and 4), MboI (lanes 5 and 6), or Sau3AI (lanes 7 and
8). DpnI, MboI, and Sau3A1 cut GATC sequences that are adenine methylated, adenine non-methylated, or
cytosine non-methylated GATC sites, respectively. Sizes of selected molecular weight standards (mws) of λ
DNAMono cut mix (New England Biolabs) are shown on the left in base pairs.
doi:10.1371/journal.pone.0155798.g003
Dam Is Expendable for B. hermsii Infection
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to establish persistent infection in a mammalian host was investigated. In doing so, two groups
of 8 immunocompetent B6 (C57/BL6NHsd) mice each were needle inoculated with either
BhΔdam or wild type B. hermsii at 1 x 106 total spirochetes per animal. Blood was collected
from each mouse every day for ten days post infection and evaluated for the presence of spiro-
chetemia by blood culture. Thirteen immunodeficient SCID mice were also inoculated along-
side immunocompetent mice with either BhΔdam (8 animals) or wild type B. hermsii (5
animals) to serve as an infection control. SCID mice lack antibody production, including the
Fig 4. In vitro growth curves of wild type B. hermsii and BhΔdam.Wild type B. hermsii is shown with black circles; BhΔdam is shown
with white triangles. No significant differences in growth rate or maximum cell density were detected between BhΔdam and wild type B.
hermsii. The mean and standard deviation of triplicate measurements at each time point are plotted.
doi:10.1371/journal.pone.0155798.g004
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borreliacidal immunoglobulin M (IgM) antibodies that are rapidly produced after host infec-
tion and known to be critical for control of B. hermsii infection [38–41].
The wild type clone was able to establish infection in all 8 immunocompetent animals and
were continuously detectable in most mice (7/8) throughout the ten-day period (Table 2). Sim-
ilarly, BhΔdam was also detected in all mice by day 1 post inoculation, and could be recovered
each day throughout the study period. Statistically-significant differences in the number of
blood-culture positive mice between the two groups were observed only on day 8, where fewer
mice produced detectable wild type spirochetemia. The finding that spirochetes were recovered
in most mice on days 9 and 10, however, indicate that wild type spirochetes remained persis-
tent throughout the study period, and that the few positive mice found on day 8 were likely a
detection artifact due to low levels of spirochetemia at that particular timepoint. Similarly, for
SCID mice, the results showed that 8/8 mice inoculated with the BhΔdammutant clone and 5/
5 mice inoculated with wild type were culture-positive for spirochetes throughout the 10 day
period (Table 2), except one wild type-infected mouse that did not produce a positive culture
until day 2 post inoculation.
To ensure the stable disruption of dam, DNA was extracted from spirochetes recovered on
day 10 post infection from immunocompetent mice and subjected to restriction enzyme analy-
sis with DpnI and MboI (S1 Fig). Spirochetal DNA at this time point was found to lack methyl-
ation, indicating that dam function was destroyed throughout the study period. Finally, PCR
amplification and sequencing of the variable major protein expression site of spirochetes recov-
ered from 3 mice in each group at day 10 post infection revealed that the locus had undergone
antigenic variation (S1 File). Previous studies have shown that antigenic switching in wild type
B. hermsii occurs via a gene conversion event at this single, transcriptionally active locus [42–
44]. Antigenic variation has also been demonstrated to be required for persistence of this path-
ogen in immunocompetent mammalian hosts [36]. Specifically, all 3 mice in the BhΔdam
group were determined to have switched from the infecting serotype of VlpA7 to VlpA25.
Overall, the data demonstrate that the disruption of Dam function by integration of gentR into
dam is stable, and that Dam is dispensable for infection and persistence in immunocompetent
murine host.
Table 2. Infection by B. hermsiiwild type and BhΔdam in B6 and SCIDmice as determined by blood
culture.
Day post infection B6 mice infected with: SCID mice infected with:
WT BhΔdam WT BhΔdam
1 8/8 8/8 4/5a 8/8
2 8/8 8/8 5/5 8/8
3 8/8 8/8 5/5 8/8
4 8/8 8/8 5/5 8/8
5 8/8 8/8 5/5 8/8
6 8/8 8/8 5/5 8/8
7 7/8 8/8 5/5 8/8
8 3/8 8/8 b 5/5 8/8
9 6/8 8/8 5/5 8/8
10 7/8 8/8 5/5 8/8
a Values listed correspond to number of positive cultures/number tested.
b Statistically-significant difference between mutant and control groups as determined by Fisher’s Exact
Test (p<0.05).
doi:10.1371/journal.pone.0155798.t002
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Despite the ability of BhΔdam to infect and persist in the murine host, it remained unclear
whether disruption of dam results in an attenuation of B. hermsii in vivo. To ascertain the role
of dam in spirochetal fitness during murine infection, qPCR quantification of spirochetemia
was employed. For this assay, two groups of 5 B6 mice were infected with 1 x 106 wild type B.
hermsii or BhΔdam. Blood samples were collected on days 3, 7, and 10 post inoculation, and
total DNA was extracted to be used as a template for qPCR. These time points were selected
because in our hands, wild type B. hermsii typically achieves peaks of spirochetemia at days 3
and 7 post inoculation, and day 10 concludes the experiment. In B6 mice, mean spirochete
density of BhΔdam at all three timepoints was not significantly different from wild type B.
hermsii (Fig 5A and 5B, data in S1 Table). To determine whether the spirochete density of the
BhΔdammutant achieved similar levels as the wild type strain in the less stringent host envi-
ronment of an immunodeficient mouse, blood from 5 SCID mice inoculated with wild type or
mutant strains was also used as a template for qPCR on days 3, 7, and 10. Both strains pro-
duced high density spirochetemia in SCID mice, but the spirochete burden in mice infected
with BhΔdam at all 3 time points was found to be significantly lower than those infected with
wild type B. hermsii (p<0.01; Fig 5C and 5D, data inS1 Table). While qPCR results demon-
strate statistically significant differences in SCID mice, the biological relevance of these results
is unknown and warrants further investigation. Nevertheless, the qPCR results from both
immunocompetent and immunodeficient mice demonstrate that dam does not impart B.
hermsii with a substantial in vivo fitness advantage, because the spirochete density of BhΔdam
in the blood remains grossly elevated at all three time points in both strains of mice. This, com-
bined with the detection of spirochetes in most mice throughout the 10 day experiment, indi-
cates that dam is dispensable for murine infection and persistence.
BhΔdam is capable of infection at low doses
To evaluate whether BhΔdam retained its ability to infect mice at low doses, 5 groups of B6 and
SCID mice, composed of 6 and 3 animals per group respectively, were infected with decreasing
doses of wild type B. hermsii or BhΔdam (approximately 1 x 105, 104, 103, 102, and 10 spiro-
chetes per inoculum). Blood samples were taken from each mouse every day until day 3 post
inoculation and monitored by blood culture for the presence of spirochetes. In B6 mice, all
doses of wild type B. hermsii and BhΔdam resulted in infection by day 2 post inoculation
(Table 3). Likewise, for the SCID mice, all infectious doses produced positive spirochetemia for
both wild type and BhΔdam throughout the 3 day study (S2 Table). The data indicate that the
overall ability of BhΔdam to infect the murine host is independent of dose and similar to wild
type B. hermsii.
Attempted complementation of the BhΔdammutant
Despite clear evidence that disruption of the bh0463A gene of B. hermsii results in a loss of ade-
nine-specific DNA methylation, gene complementation was attempted in order to verify that
the difference between the infection profiles of B. hermsii wild type and BhΔdam were due
exclusively to the disruption of dam. Initially, a shuttle vector was generated that would allow
for in trans complementation using methods described in Battisti et al. [27]. Attempts to trans-
form wild type B. hermsii with the shuttle vector resulted in either no transformants, or integra-
tion of the plasmid into the genome. In another effort, a construct was generated that would
replace the disrupted dam gene with a wild type copy that included a downstream kanamycin
resistance cassette (kanR) in cis. Two transformations were attempted; both resulted in trans-
formants with inappropriate rearrangements at the dam locus. A final attempt to complement
dam in trans on a 200 kilobase linear plasmid of B. hermsii via allelic exchange utilizing
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methods described in Fine et al. also failed [31]. No transformants resulted from this effort.
Thus far, all attempts to complement the BhΔdammutant clone have been unsuccessful.
In an effort to verify that the disruption of dam results in an inability to persist in the
absence of a complemented mutant, a second independently-generated clone of BhΔdam
(BhΔdam#2) was generated, characterized, and used to infect B6 mice and SCID mice. Trans-
formation and verification of BhΔdam#2 was carried out by sequencing and restriction enzyme
digestion as described for the first clone (S2 Fig). In vitro growth curves comparing BhΔdam#2
to wild type B. hermsii during 3 days of exponential growth (days 1–4 post inoculation)
revealed that BhΔdam#2 grew significantly faster than the control strain as determined by lin-
ear regression analysis and comparison of the slopes (S3 Fig; p = 0.005). Correspondingly, the
Fig 5. BhΔdam persists in the blood of B6 and SCIDmice. Spirochetemia as determined by qPCR for A) wild type (WT) B. hermsii in B6 mice;
B) BhΔdam in B6 mice; C) WT B. hermsii in SCID mice; and D) BhΔdam in SCID mice. Differences in spirochetemic density between strains at
days 3, 7, and 10 post infection in B6 mice were not statistically significant (p>0.05). Conversely, in SCID mice, spirochetemia of BhΔdam at all
timepoints was significantly lower thanWT B. hermsii (p<0.01, denoted by an asterisk). Spirochetemia from each mouse is represented by a
different shape; mean density is depicted by a line.
doi:10.1371/journal.pone.0155798.g005
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doubling time for BhΔdam#2 was 8.8 hours, while the doubling time for wild type was 10.2
hours. Mean maximum cell density was not significantly different between the two strains
(BhΔdam#2 = 2.8 x 108 spirochetes per mL, 95% CI = 2.1 x 108–3.6 x 108; wild type = 2.2 x 108,
95% CI = 1.6 x 108–2.7 x 108; p = 0.2), although BhΔdam#2 reached maximum cell density on
day 4 post inoculation while wild type B. hermsii peaked at day 6. Finally, B6 and SCID mice
were inoculated with 1 x 106 spirochetes, and infection was monitored by blood culture each
day for 10 days post inoculation. Like the first clone, all SCID and B6 mice were positive
throughout the 10 day experiment (S3 Table), except one SCID mouse that did not become
positive until day 2. Together, the results from the second clone further support that the dis-
ruption of dam does not result in in vitro growth deficiencies, nor does it result in significant in
vivo attenuation leading a lack of persistence. Despite the absence of a complement, two clones
of BhΔdam exhibiting similar infection phenotypes provides confidence that Dam is dispens-
able for mammalian infection and persistence.
Discussion
It has been previously reported that adenine methylation systems are found in relapsing fever
Borrelia spp., but are absent in most B. burgdorferi strains [22, 23]. Correspondingly, a putative
Dam is encoded in the chromosome of Borrelia recurrentis and B. duttonii, but not in B. burg-
dorferi [9]. For the present study, analyses with BLAST and the Restriction Enzyme Database
(http://rebase.neb.com) revealed that an orthologous gene with a putative Dam function exists
in B. hermsii at chromosomal locus bh0463A (GenBank Accession Number NC_010673.1),
and is conserved in other relapsing fever-type Borrelia. After cloning the B. hermsii gene into a
dam- E. coli strain, extracted DNA was digested with restriction enzymes sensitive to adenine
methylation. The resulting restriction fragment profile provided strong evidence that bh0463A
is indeed an adenine-specific methyltransferase. Because of the role for DNAmethylation in
the virulence of other pathogens, the presence of dam in B. hermsii led to the hypothesis that
the gene product serves a role in host pathogenicity. The findings reported here are the first to
show that disruption of dam in a relapsing fever-type Borrelia species does not result in signifi-
cant in vitro or in vivo attenuation, a rather surprising finding based on studies involving dam-
strains of other important pathogens [10, 12, 37].
The finding that mean spirochete density is significantly lower for BhΔdam at days 3, 7, and
10 post inoculation compared to the wild type strain in SCID mice is somewhat puzzling, as
this difference is not observed when the mutant clone is inoculated into the more taxing envi-
ronment of the immunocompetent host. Whether this finding is biologically relevant must be
examined more closely, as the overall spirochete burden of the mutant strain in SCID mice was
Table 3. Infection of B6 mice with wild type B. hermsii and BhΔdam at decreasing infectious doses of approximately 1 x 105 to 10 spirochetes.
Day post inoculation: B6 mice inoculated with:
WT BhΔdam
105 104 103 102 10 105 104 103 102 10
1 5/6a 4/6 6/6 6/6 5/6 5/6 3/6 2/6 2/6 0/6b
2 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
3 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6 6/6
a Values listed correspond to number of positive mice/number tested.
b Statistically-significant difference between mutant and control groups as determined by Fisher’s Exact Test (p<0.05). Note that a complemented mutant
was not generated for comparison (see below).
doi:10.1371/journal.pone.0155798.t003
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grossly elevated, as expected. The apparently subtle differences between strains, and their inter-
actions with the host’s immune system, will be evaluated in forthcoming studies using a larger
sample size and increasing the sampling frequency. Nevertheless, the results reported herein
demonstrate that the B. hermsii Dam is dispensable for murine infection and persistence.
The hallmark of relapsing fever is the repeated waxing and waning of spirochetemia that
parallels febrile episodes [5]. The episodic outgrowth of each peak is dominated by a single
serotype of the variable major protein (Vmp) [45]. The B. hermsii genome harbors a large rep-
ertoire of non-expressed vmp genes that are switched via gene conversion into the single tran-
scriptionally-active expression site during infection of a mammalian host [42, 43, 46]. The
overall result of this antigenic variation system is that it provides the spirochete with the capac-
ity to repeatedly evade the highly serotype-specific host humoral response [41, 47]. Antigenic
switching is required for spirochete persistence in mice beyond the first wave of spirochetemia,
which typically peaks on day 3 post infection [36, 39]. By day 10 post infection, when antigenic
variation was confirmed in BhΔdam, it would be expected that all spirochetes in the infecting
inoculum, even minor serotypes if present, would have undergone switching or be cleared. By
this point, each immunocompetent mouse would be expected to have undergone 1–2 relapses
[36, 39]. While antigenic switching was verified to occur in BhΔdam, it is not clear whether the
kinetics of such switching could be mediated by Dam. Increased antigenic switch rates in
BhΔdammay explain why the mutant was detected each day throughout the B6 murine infec-
tion experiment, while wild type B. hermsii could not be recovered on low density days. More-
over, in a report by Barbour et al. that describes a loose, programmed order for within-host
antigenic variation in B. hermsii, certain serotypes appeared more frequently than others when
infected with spirochetes of the serotype VlpA7 [48]. Interestingly, while BhΔdam underwent
antigenic switching, spirochetes from all three mice switched to the same serotype (VlpA25), a
serotype that was not identified with any frequency in the reported findings by Barbour et al.
This raises the possibility that the absence of Dam disrupts the programmed order for antigenic
switching in B. hermsii. Future studies should include a closer examination of the role for Dam
in immune evasion, both in the rate and order of Vmp switching, and in mechanisms for early
IgM immune escape.
The data clearly indicate that Dam is not absolutely required for infection or persistence in
our murine model, but the presence of dam orthologs in numerous relapsing fever Borrelia spp.
raises the question of why the gene is so highly conserved in these spirochetes. One possibility
is that Dammay be essential in some component of the life cycle of B. hermsii that is not recre-
ated in the laboratory. In nature, the spirochete must be capable of survival in diverse reservoir
species, and thrive under the pressure of co-infecting pathogens and bacteriophages. In this con-
text, even small reductions in replication rate, as was observed in B6 and SCIDmice immediately
post infection, may adversely affect the propagation of this pathogen. Another explanation for
the conservation of Dam is that it may serve a role in the tick phase of the B. hermsii lifecycle, or
in the regulation of differential gene expression as the spirochete moves between the mammalian
host and tick vector. For example, in the tick phase of the B. hermsii lifecycle, vmp transcription
is turned ‘OFF’, while another distant site required for tick transmission, vtp (variable tick pro-
tein), is turned ‘ON’ [36, 49]. While both Vtp and Vmp are required for the B. hermsii lifecycle,
the mechanisms regulating their mutually exclusive expression remains unknown [36, 39]. The
absence of the Dam gene in B. burgdorferi, however, supports that if dam is involved in differen-
tial gene regulation in the tick, it is uniquely required for relapsing fever spirochetes. Indeed, sig-
nificant differences between the two groups exist, with many relapsing fever-type Borrelia being
transmitted by the soft-bodied, fast-feedingOrnithodoros spp. ticks, while B. burgdorferi requires
the hard-bodied, slow-feeding Ixodes tick [50, 51]. Whether dam is required for the tick phase of
relapsing fever spirochetes will be the subject of forthcoming studies.
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Ideally, the results herein would be supported by a mutant clone complemented with the
bh0463A gene. Although complementation of B. hermsii has been successful for other groups
[27, 36, 52], all attempts to generate a dam complement failed. Despite the published descrip-
tions of numerous complementation mutants of B. burgdorferi, difficulties in genetic comple-
mentation of Borrelia have been documented [53, 54]. A major limitation of not having a
complement is our inability to test whether the disruption of dam resulted in polar effects on
adjacent genes. Polar effects, however, are unlikely due to the fact that significant phenotypic
differences were not observed between wild type B. hermsii and BhΔdam. Moreover, both
bh0463A and gentR genes are transcribed in the same direction, and none of the native
sequence was deleted in BhΔdam. Thus, the native terminator sequence is expected to termi-
nate the mutant transcript in the same fashion as the wild type transcript, further minimizing
the likelihood that polar effects had any impact on a possible mutant phenotype. Despite the
lack of a complement, the absence of significant differences of two independently-generated
clones of BhΔdam in regard to in vitro growth, infectivity, and in vivo persistence, along with
restriction fragment evidence for the disruption of Dam function prior to and after murine
infection, instills confidence in the validity of the results: the absence of adenine-specific DNA
methylation does not result in marked phenotypic differences during mammalian infection.
The present data indicate that dam does not influence the ability of B. hermsii to infect or
persist in the mammalian host. In addition to characterizing the role for dam in the arthropod
portion of the lifecycle, it would also be prudent to investigate the utility of BhΔdam as a molec-
ular tool. For example, the role for DNA adenine methylation in restriction modification sys-
tems and in DNA partitioning have been well established [10, 11]. Therefore, future studies
will be directed toward understanding whether BhΔdam provides improved transformation
efficiency when generating genetic mutants, and determining if the absence of Dam activity
allows for B. hermsii plasmid loss. Unlike B. burgdorferi, the B. hermsii genome is stable follow-
ing transformation and in vitro passage [31, 55, 56]. Both tools have the potential to improve
the investigation of putative virulence factors, and provide insight into the evolution of various
relapsing fever and Lyme Borrelia spp.
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S1 Fig. BhΔdam remains Dam deficient on day 10 post inoculation. Pooled BhΔdam DNA
extracted from 5 B6 mice on day 10 post inoculation was subjected to DpnI and MboI restric-
tion enzyme digestion to verify the stable disruption of Dam function. DpnI and MboI cleave
sequences that are adenine methylated and adenine non-methylated, respectively. Sizes of
selected molecular weight standards (mws) of 100 bp DNA ladder (New England Biolabs) are
shown on the left in base pairs.
(TIF)
S2 Fig. Verification of Dam disruption in BhΔdam#2 by restriction enzyme digestion.
DNA from BhΔdam#2 is either undigested, or digested with DpnI, MboI, or Sau3AI. DpnI,
MboI, and Sau3A1 cut GATC sequences that are adenine methylated, adenine non-methylated,
or cytosine non-methylated GATC sites, respectively. The absence of DNA cleavage with DpnI
digestion and fragmentation with MboI digestion verifies the disruption of Dam function.
(TIF)
S3 Fig. In vitro growth curves of wild type B. hermsii and BhΔdam#2.Wild type B. hermsii is
shown with black circles; BhΔdam#2 is shown with white triangles. The mean and standard
deviation of triplicate measurements at each time point are plotted.
(TIF)
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prior to infection compared to the sequences of vmp from BhΔdam recovered from 3 mice
on day 10 post infection. Through sequencing of vmp and BLAST analysis, the vmp serotype
in the infecting inoculum was determined to be VlpA7. The vmp serotype of BhΔdam recov-
ered from all B6 mice on day 10 was determined to be VlpA25.
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BhΔdam at days 3, 7, and 10 post inoculation.
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